{"gene":"FTCD","run_date":"2026-06-09T23:54:44","timeline":{"discoveries":[{"year":2000,"finding":"Human FTCD encodes a bifunctional enzyme (formiminotransferase cyclodeaminase) that links histidine catabolism to folate metabolism; the two enzymatic domains show high sequence similarity to two distinct bacterial open reading frames, suggesting eukaryotic FTCD arose by gene fusion. The protein is 541 amino acids and is highly expressed in liver.","method":"cDNA cloning, sequence analysis, domain homology to bacterial ORFs, tissue expression analysis","journal":"Cytogenetics and cell genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — cloning and sequence-based domain analysis with tissue expression; no in vitro enzymatic reconstitution or mutagenesis in abstract, but finding is independently consistent with known biochemistry","pmids":["10773664"],"is_preprint":false},{"year":2021,"finding":"FTCD was identified as a novel p47-binding protein that localizes primarily to the Golgi complex. FTCD binds to either p47 or p97 via their polyglutamate motifs and functions in p97/p47-mediated Golgi reassembly during mitosis both in vivo and in vitro. FTCD, p47, and p97 form a large FTCD-p97/p47-FTCD tethering complex; an engineered mitochondria-targeted FTCD caused mitochondrial aggregation at mitosis by recruiting endogenous p97 and p47, establishing FTCD as a membrane tethering factor in p97/p47-mediated Golgi membrane fusion.","method":"Co-immunoprecipitation, in vitro binding assays, in vivo and in vitro Golgi reassembly assay, mitochondria retargeting tethering assay, domain mutagenesis (polyglutamate motif)","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal binding assays, in vitro reconstitution of Golgi reassembly, orthogonal in vivo tethering assay with mitochondria retargeting, domain-level dissection; multiple orthogonal methods in single rigorous study","pmids":["33555040"],"is_preprint":false},{"year":2023,"finding":"Hepatocyte-specific knockout of FTCD in mice promotes both carcinogen-induced and spontaneous hepatocarcinogenesis. Mechanistically, loss of FTCD upregulates PPARγ and SREBP2 by activating the PTEN/Akt/mTOR signalling axis, leading to lipid accumulation and hepatocarcinogenesis.","method":"Liver-specific Ftcd knockout mouse model, diethylnitrosamine-induced HCC, multi-omics (transcriptomics, metabolomics, proteomics), functional and biochemical studies, Akt inhibitor rescue experiments","journal":"JHEP reports : innovation in hepatology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — clean liver-specific KO with defined phenotypic readout, multi-omics mechanistic dissection, pharmacological rescue; single lab but multiple orthogonal methods","pmids":["37675273"],"is_preprint":false},{"year":2021,"finding":"Restoration of FTCD expression in HCC cells (via nanoparticle-delivered FTCD plasmid) reduced intracellular tetrahydrofolate (THF) levels, inhibited NADPH/NADP+ and GSH/GSSG ratios, induced reactive oxygen species generation and mitochondrial oxidative stress, triggered cytochrome c release with opening of the mitochondrial permeability transition pore, and activated caspase-dependent apoptosis, suppressing HCC proliferation in vitro and in vivo.","method":"FTCD plasmid overexpression in HCC cells via HMON nanoparticles, THF measurement, NADPH/NADP+ and GSH/GSSG ratio assays, ROS assay, cytochrome c release, caspase activation, in vitro and in vivo tumor growth assays","journal":"International journal of pharmaceutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with multiple biochemical readouts in vitro and in vivo; single lab, no direct enzymatic reconstitution","pmids":["34774692"],"is_preprint":false},{"year":2019,"finding":"A missense variant in FTCD (rs61735836, p.Val101Met) is associated with reduced arsenic metabolism efficiency (increased urinary iAs%, increased MMA%, decreased DMA%), consistent with FTCD's role in histidine catabolism generating one-carbon units that enter the folate cycle providing methyl groups for arsenic methylation. The major/high-efficiency allele (G/Valine) is human-specific and eliminates a start codon at the first 5'-proximal Kozak sequence, suggesting selection against an alternative translation start site.","method":"Exome-wide association study in 1,660 Bangladeshi individuals; urinary arsenic metabolite measurements; linkage disequilibrium analysis; Kozak sequence analysis","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — human genetic association linking coding variant to enzymatic pathway efficiency, replicated across multiple arsenic metabolite phenotypes; no direct enzymatic assay of variant protein","pmids":["30893314"],"is_preprint":false},{"year":2024,"finding":"Cabozantinib treatment of lenvatinib-resistant HCC cells (Hep3B-LR) restores FTCD protein expression, which is downregulated during acquisition of lenvatinib resistance; proteome analysis of xenografts confirmed FTCD upregulation by cabozantinib, and western blot and immunohistochemistry validated this result.","method":"Lenvatinib-resistant cell line generation, proteome analysis of xenograft tissues, western blot, immunohistochemistry, microarray/qPCR","journal":"Biochemical pharmacology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, descriptive association between drug treatment and FTCD protein level; no direct mechanistic experiment establishing how cabozantinib restores FTCD","pmids":["38815631"],"is_preprint":false}],"current_model":"FTCD is a bifunctional liver-enriched enzyme (formiminotransferase cyclodeaminase) that arose by gene fusion and links histidine catabolism to one-carbon/folate metabolism; beyond its metabolic role, FTCD localizes to the Golgi and acts as a membrane tethering factor by forming a FTCD-p97/p47-FTCD complex that drives Golgi reassembly during mitosis, while loss of FTCD in hepatocytes activates the PTEN/Akt/mTOR axis to upregulate PPARγ and SREBP2, promoting lipid accumulation and hepatocarcinogenesis."},"narrative":{"mechanistic_narrative":"FTCD is a liver-enriched bifunctional enzyme (formiminotransferase cyclodeaminase) that links histidine catabolism to one-carbon/folate metabolism and most likely arose by fusion of two ancestral bacterial enzymatic domains [PMID:10773664]. Beyond this metabolic activity, FTCD is a Golgi-localized membrane tethering factor: it binds the polyglutamate motifs of p47 or p97 to assemble a large FTCD-p97/p47-FTCD complex that drives p97/p47-mediated Golgi membrane fusion and reassembly during mitosis, and an engineered mitochondria-targeted FTCD recruits endogenous p97 and p47 to aggregate mitochondria, establishing FTCD's intrinsic tethering function [PMID:33555040]. In the liver, FTCD acts as a tumor suppressor: hepatocyte-specific loss promotes both carcinogen-induced and spontaneous hepatocarcinogenesis by activating the PTEN/Akt/mTOR axis to upregulate PPARγ and SREBP2, driving lipid accumulation [PMID:37675273], whereas restoring FTCD in HCC cells depletes tetrahydrofolate, lowers NADPH and GSH ratios, and triggers ROS-driven mitochondrial oxidative stress, cytochrome c release, and caspase-dependent apoptosis [PMID:34774692]. A human FTCD missense variant (p.Val101Met) reduces arsenic methylation efficiency, consistent with FTCD supplying folate-cycle one-carbon units for methylation reactions [PMID:30893314].","teleology":[{"year":2000,"claim":"Established the molecular identity of FTCD as a bifunctional histidine-catabolic enzyme connecting to folate metabolism, framing it as a metabolic gene of likely fusion origin.","evidence":"cDNA cloning, sequence/domain homology to two bacterial ORFs, and liver-enriched tissue expression analysis","pmids":["10773664"],"confidence":"Medium","gaps":["No in vitro enzymatic reconstitution or mutagenesis of the catalytic domains","Fusion origin inferred from homology, not experimentally validated","No structural model of the bifunctional protein"]},{"year":2019,"claim":"Linked FTCD genotype to one-carbon metabolic output in humans, showing its histidine-derived folate cycle activity supplies methyl groups relevant to arsenic methylation.","evidence":"Exome-wide association in 1,660 Bangladeshi individuals with urinary arsenic metabolite phenotypes and Kozak/start-codon analysis","pmids":["30893314"],"confidence":"Medium","gaps":["No direct enzymatic assay of the variant protein","Causality of the coding change versus linked regulatory effects not resolved","Mechanism connecting FTCD activity to methylarsenical output not biochemically dissected"]},{"year":2021,"claim":"Revealed a moonlighting structural role distinct from metabolism — FTCD is a membrane tethering factor for Golgi reassembly — answering how Golgi membranes are bridged during p97/p47-mediated fusion.","evidence":"Co-IP, reciprocal in vitro binding via polyglutamate motifs, in vitro and in vivo Golgi reassembly assays, and mitochondria-retargeting tethering assay","pmids":["33555040"],"confidence":"High","gaps":["Structural basis of the FTCD-p97/p47-FTCD complex not solved","Relationship between catalytic and tethering functions unclear","Whether tethering is regulated through the cell cycle not defined"]},{"year":2021,"claim":"Connected restoration of FTCD to tumor suppression mechanistically, showing it perturbs folate/redox metabolism to drive mitochondrial apoptosis in HCC.","evidence":"Nanoparticle-delivered FTCD overexpression in HCC cells with THF, NADPH/NADP+, GSH/GSSG, ROS, cytochrome c, caspase, and in vivo tumor readouts","pmids":["34774692"],"confidence":"Medium","gaps":["Single lab without direct enzymatic reconstitution","Whether the apoptotic effect requires FTCD catalytic activity not tested","Off-target effects of nanoparticle delivery not excluded"]},{"year":2023,"claim":"Demonstrated FTCD is a hepatic tumor suppressor in vivo and defined the signalling cascade through which its loss promotes lipid accumulation and cancer.","evidence":"Hepatocyte-specific Ftcd knockout mice, DEN-induced HCC, multi-omics, and Akt inhibitor rescue","pmids":["37675273"],"confidence":"High","gaps":["How metabolic FTCD loss mechanistically engages PTEN/Akt/mTOR not fully resolved","Contribution of the Golgi tethering function to tumor suppression untested","Direct molecular target linking FTCD to PTEN regulation unknown"]},{"year":2024,"claim":"Associated FTCD expression with therapy response, noting its downregulation in lenvatinib-resistant HCC and restoration by cabozantinib.","evidence":"Lenvatinib-resistant cell lines, xenograft proteomics, western blot, and immunohistochemistry","pmids":["38815631"],"confidence":"Low","gaps":["Descriptive association only — no mechanism by which cabozantinib restores FTCD","Causal role of FTCD in resistance not established","Not independently confirmed"]},{"year":null,"claim":"How FTCD's metabolic enzymatic function, its Golgi membrane-tethering role, and its tumor-suppressor signalling are mechanistically integrated remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structure of the catalytic or tethering complex","Whether catalytic activity is required for tumor suppression or tethering untested","Direct molecular link between FTCD loss and PTEN/Akt/mTOR activation unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0]},{"term_id":"GO:0016829","term_label":"lyase activity","supporting_discovery_ids":[0]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1]}],"localization":[{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,4]},{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[1]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3]}],"complexes":["FTCD-p97/p47-FTCD tethering complex"],"partners":["NSFL1C","VCP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O95954","full_name":"Formimidoyltransferase-cyclodeaminase","aliases":["Formiminotransferase-cyclodeaminase","FTCD","LCHC1"],"length_aa":541,"mass_kda":58.9,"function":"Folate-dependent enzyme, that displays both transferase and deaminase activity. Serves to channel one-carbon units from formiminoglutamate to the folate pool Binds and promotes bundling of vimentin filaments originating from the Golgi","subcellular_location":"Cytoplasm, cytosol; Golgi apparatus; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, centriole","url":"https://www.uniprot.org/uniprotkb/O95954/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/FTCD","classification":"Not Classified","n_dependent_lines":24,"n_total_lines":1208,"dependency_fraction":0.019867549668874173},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/FTCD","total_profiled":1310},"omim":[{"mim_id":"613065","title":"LEUKEMIA, ACUTE LYMPHOBLASTIC; ALL","url":"https://www.omim.org/entry/613065"},{"mim_id":"609457","title":"HISTIDINE AMMONIA-LYASE; HAL","url":"https://www.omim.org/entry/609457"},{"mim_id":"606806","title":"FORMIMINOTRANSFERASE CYCLODEAMINASE; FTCD","url":"https://www.omim.org/entry/606806"},{"mim_id":"606664","title":"GLYCINE N-METHYLTRANSFERASE DEFICIENCY","url":"https://www.omim.org/entry/606664"},{"mim_id":"606628","title":"GLYCINE N-METHYLTRANSFERASE; GNMT","url":"https://www.omim.org/entry/606628"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Cytosol","reliability":"Approved"},{"location":"Plasma membrane","reliability":"Additional"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"liver","ntpm":914.3}],"url":"https://www.proteinatlas.org/search/FTCD"},"hgnc":{"alias_symbol":[],"prev_symbol":[]},"alphafold":{"accession":"O95954","domains":[{"cath_id":"3.30.990.10","chopping":"5-179","consensus_level":"high","plddt":96.7633,"start":5,"end":179},{"cath_id":"3.30.70.670","chopping":"183-273","consensus_level":"medium","plddt":96.9907,"start":183,"end":273},{"cath_id":"1.20.120.680","chopping":"339-539","consensus_level":"high","plddt":95.5114,"start":339,"end":539}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O95954","model_url":"https://alphafold.ebi.ac.uk/files/AF-O95954-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O95954-F1-predicted_aligned_error_v6.png","plddt_mean":95.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=FTCD","jax_strain_url":"https://www.jax.org/strain/search?query=FTCD"},"sequence":{"accession":"O95954","fasta_url":"https://rest.uniprot.org/uniprotkb/O95954.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O95954/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O95954"}},"corpus_meta":[{"pmid":"10773664","id":"PMC_10773664","title":"Cloning and characterization of human FTCD on 21q22.3, a candidate gene for glutamate formiminotransferase deficiency.","date":"2000","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10773664","citation_count":34,"is_preprint":false},{"pmid":"37675273","id":"PMC_37675273","title":"Loss of hepatic FTCD promotes lipid accumulation and hepatocarcinogenesis by upregulating PPARγ and SREBP2.","date":"2023","source":"JHEP reports : innovation in hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37675273","citation_count":26,"is_preprint":false},{"pmid":"30893314","id":"PMC_30893314","title":"A missense variant in FTCD is associated with arsenic metabolism and toxicity phenotypes in Bangladesh.","date":"2019","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/30893314","citation_count":26,"is_preprint":false},{"pmid":"33555040","id":"PMC_33555040","title":"p97 and p47 function in membrane tethering in cooperation with FTCD during mitotic Golgi reassembly.","date":"2021","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/33555040","citation_count":16,"is_preprint":false},{"pmid":"30784016","id":"PMC_30784016","title":"The Diagnostic Value of Arginase-1, FTCD, and MOC-31 Expression in Early Detection of Hepatocellular Carcinoma (HCC) and in Differentiation Between HCC and Metastatic Adenocarcinoma to the Liver.","date":"2020","source":"Journal of gastrointestinal cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30784016","citation_count":16,"is_preprint":false},{"pmid":"34774692","id":"PMC_34774692","title":"Hollow mesoporous organosilica nanotheranostics incorporating formimidoyltransferase cyclodeaminase (FTCD) plasmids for magnetic resonance imaging and tetrahydrofolate metabolism fission on hepatocellular carcinoma.","date":"2021","source":"International journal of pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/34774692","citation_count":9,"is_preprint":false},{"pmid":"38414493","id":"PMC_38414493","title":"Anodal transcranial direct current stimulation (atDCS) and functional transcranial Doppler sonography (fTCD) in healthy elderly and patients with MCI: modulation of age-related changes in word fluency and language lateralization.","date":"2024","source":"Frontiers in aging","url":"https://pubmed.ncbi.nlm.nih.gov/38414493","citation_count":3,"is_preprint":false},{"pmid":"29927301","id":"PMC_29927301","title":"A functional promoter variant of the human formimidoyltransferase cyclodeaminase (FTCD) gene is associated with working memory performance in young but not older adults.","date":"2018","source":"Neuropsychology","url":"https://pubmed.ncbi.nlm.nih.gov/29927301","citation_count":3,"is_preprint":false},{"pmid":"38815631","id":"PMC_38815631","title":"Cabozantinib inhibits the growth of lenvatinib-resistant hepatoma cells restoring FTCD expression.","date":"2024","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38815631","citation_count":3,"is_preprint":false},{"pmid":"39824452","id":"PMC_39824452","title":"AFB1 consolidates HBV harm to induce liver injury and carcinogenic risk by inactivating FTCD-AS1-PXR-MASP1 axis.","date":"2025","source":"Toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/39824452","citation_count":2,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.07.20.665220","title":"Visual stimulus-evoked blood velocity responses in individual human posterior cerebral arteries measured with dynamic phase-contrast functional MR angiography","date":"2025-07-25","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.20.665220","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.15.613144","title":"Filter bank common spatial pattern and envelope-based features in multimodal EEG-fTCD brain-computer interfaces","date":"2024-09-19","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.15.613144","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9020,"output_tokens":1875,"usd":0.027592,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8829,"output_tokens":2631,"usd":0.05496,"stage2_stop_reason":"end_turn"},"total_usd":0.082552,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"Human FTCD encodes a bifunctional enzyme (formiminotransferase cyclodeaminase) that links histidine catabolism to folate metabolism; the two enzymatic domains show high sequence similarity to two distinct bacterial open reading frames, suggesting eukaryotic FTCD arose by gene fusion. The protein is 541 amino acids and is highly expressed in liver.\",\n      \"method\": \"cDNA cloning, sequence analysis, domain homology to bacterial ORFs, tissue expression analysis\",\n      \"journal\": \"Cytogenetics and cell genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — cloning and sequence-based domain analysis with tissue expression; no in vitro enzymatic reconstitution or mutagenesis in abstract, but finding is independently consistent with known biochemistry\",\n      \"pmids\": [\"10773664\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"FTCD was identified as a novel p47-binding protein that localizes primarily to the Golgi complex. FTCD binds to either p47 or p97 via their polyglutamate motifs and functions in p97/p47-mediated Golgi reassembly during mitosis both in vivo and in vitro. FTCD, p47, and p97 form a large FTCD-p97/p47-FTCD tethering complex; an engineered mitochondria-targeted FTCD caused mitochondrial aggregation at mitosis by recruiting endogenous p97 and p47, establishing FTCD as a membrane tethering factor in p97/p47-mediated Golgi membrane fusion.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assays, in vivo and in vitro Golgi reassembly assay, mitochondria retargeting tethering assay, domain mutagenesis (polyglutamate motif)\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal binding assays, in vitro reconstitution of Golgi reassembly, orthogonal in vivo tethering assay with mitochondria retargeting, domain-level dissection; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"33555040\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Hepatocyte-specific knockout of FTCD in mice promotes both carcinogen-induced and spontaneous hepatocarcinogenesis. Mechanistically, loss of FTCD upregulates PPARγ and SREBP2 by activating the PTEN/Akt/mTOR signalling axis, leading to lipid accumulation and hepatocarcinogenesis.\",\n      \"method\": \"Liver-specific Ftcd knockout mouse model, diethylnitrosamine-induced HCC, multi-omics (transcriptomics, metabolomics, proteomics), functional and biochemical studies, Akt inhibitor rescue experiments\",\n      \"journal\": \"JHEP reports : innovation in hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean liver-specific KO with defined phenotypic readout, multi-omics mechanistic dissection, pharmacological rescue; single lab but multiple orthogonal methods\",\n      \"pmids\": [\"37675273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Restoration of FTCD expression in HCC cells (via nanoparticle-delivered FTCD plasmid) reduced intracellular tetrahydrofolate (THF) levels, inhibited NADPH/NADP+ and GSH/GSSG ratios, induced reactive oxygen species generation and mitochondrial oxidative stress, triggered cytochrome c release with opening of the mitochondrial permeability transition pore, and activated caspase-dependent apoptosis, suppressing HCC proliferation in vitro and in vivo.\",\n      \"method\": \"FTCD plasmid overexpression in HCC cells via HMON nanoparticles, THF measurement, NADPH/NADP+ and GSH/GSSG ratio assays, ROS assay, cytochrome c release, caspase activation, in vitro and in vivo tumor growth assays\",\n      \"journal\": \"International journal of pharmaceutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with multiple biochemical readouts in vitro and in vivo; single lab, no direct enzymatic reconstitution\",\n      \"pmids\": [\"34774692\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"A missense variant in FTCD (rs61735836, p.Val101Met) is associated with reduced arsenic metabolism efficiency (increased urinary iAs%, increased MMA%, decreased DMA%), consistent with FTCD's role in histidine catabolism generating one-carbon units that enter the folate cycle providing methyl groups for arsenic methylation. The major/high-efficiency allele (G/Valine) is human-specific and eliminates a start codon at the first 5'-proximal Kozak sequence, suggesting selection against an alternative translation start site.\",\n      \"method\": \"Exome-wide association study in 1,660 Bangladeshi individuals; urinary arsenic metabolite measurements; linkage disequilibrium analysis; Kozak sequence analysis\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — human genetic association linking coding variant to enzymatic pathway efficiency, replicated across multiple arsenic metabolite phenotypes; no direct enzymatic assay of variant protein\",\n      \"pmids\": [\"30893314\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Cabozantinib treatment of lenvatinib-resistant HCC cells (Hep3B-LR) restores FTCD protein expression, which is downregulated during acquisition of lenvatinib resistance; proteome analysis of xenografts confirmed FTCD upregulation by cabozantinib, and western blot and immunohistochemistry validated this result.\",\n      \"method\": \"Lenvatinib-resistant cell line generation, proteome analysis of xenograft tissues, western blot, immunohistochemistry, microarray/qPCR\",\n      \"journal\": \"Biochemical pharmacology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, descriptive association between drug treatment and FTCD protein level; no direct mechanistic experiment establishing how cabozantinib restores FTCD\",\n      \"pmids\": [\"38815631\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"FTCD is a bifunctional liver-enriched enzyme (formiminotransferase cyclodeaminase) that arose by gene fusion and links histidine catabolism to one-carbon/folate metabolism; beyond its metabolic role, FTCD localizes to the Golgi and acts as a membrane tethering factor by forming a FTCD-p97/p47-FTCD complex that drives Golgi reassembly during mitosis, while loss of FTCD in hepatocytes activates the PTEN/Akt/mTOR axis to upregulate PPARγ and SREBP2, promoting lipid accumulation and hepatocarcinogenesis.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"FTCD is a liver-enriched bifunctional enzyme (formiminotransferase cyclodeaminase) that links histidine catabolism to one-carbon/folate metabolism and most likely arose by fusion of two ancestral bacterial enzymatic domains [#0]. Beyond this metabolic activity, FTCD is a Golgi-localized membrane tethering factor: it binds the polyglutamate motifs of p47 or p97 to assemble a large FTCD-p97/p47-FTCD complex that drives p97/p47-mediated Golgi membrane fusion and reassembly during mitosis, and an engineered mitochondria-targeted FTCD recruits endogenous p97 and p47 to aggregate mitochondria, establishing FTCD's intrinsic tethering function [#1]. In the liver, FTCD acts as a tumor suppressor: hepatocyte-specific loss promotes both carcinogen-induced and spontaneous hepatocarcinogenesis by activating the PTEN/Akt/mTOR axis to upregulate PPARγ and SREBP2, driving lipid accumulation [#2], whereas restoring FTCD in HCC cells depletes tetrahydrofolate, lowers NADPH and GSH ratios, and triggers ROS-driven mitochondrial oxidative stress, cytochrome c release, and caspase-dependent apoptosis [#3]. A human FTCD missense variant (p.Val101Met) reduces arsenic methylation efficiency, consistent with FTCD supplying folate-cycle one-carbon units for methylation reactions [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established the molecular identity of FTCD as a bifunctional histidine-catabolic enzyme connecting to folate metabolism, framing it as a metabolic gene of likely fusion origin.\",\n      \"evidence\": \"cDNA cloning, sequence/domain homology to two bacterial ORFs, and liver-enriched tissue expression analysis\",\n      \"pmids\": [\"10773664\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No in vitro enzymatic reconstitution or mutagenesis of the catalytic domains\", \"Fusion origin inferred from homology, not experimentally validated\", \"No structural model of the bifunctional protein\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Linked FTCD genotype to one-carbon metabolic output in humans, showing its histidine-derived folate cycle activity supplies methyl groups relevant to arsenic methylation.\",\n      \"evidence\": \"Exome-wide association in 1,660 Bangladeshi individuals with urinary arsenic metabolite phenotypes and Kozak/start-codon analysis\",\n      \"pmids\": [\"30893314\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct enzymatic assay of the variant protein\", \"Causality of the coding change versus linked regulatory effects not resolved\", \"Mechanism connecting FTCD activity to methylarsenical output not biochemically dissected\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Revealed a moonlighting structural role distinct from metabolism — FTCD is a membrane tethering factor for Golgi reassembly — answering how Golgi membranes are bridged during p97/p47-mediated fusion.\",\n      \"evidence\": \"Co-IP, reciprocal in vitro binding via polyglutamate motifs, in vitro and in vivo Golgi reassembly assays, and mitochondria-retargeting tethering assay\",\n      \"pmids\": [\"33555040\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the FTCD-p97/p47-FTCD complex not solved\", \"Relationship between catalytic and tethering functions unclear\", \"Whether tethering is regulated through the cell cycle not defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Connected restoration of FTCD to tumor suppression mechanistically, showing it perturbs folate/redox metabolism to drive mitochondrial apoptosis in HCC.\",\n      \"evidence\": \"Nanoparticle-delivered FTCD overexpression in HCC cells with THF, NADPH/NADP+, GSH/GSSG, ROS, cytochrome c, caspase, and in vivo tumor readouts\",\n      \"pmids\": [\"34774692\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab without direct enzymatic reconstitution\", \"Whether the apoptotic effect requires FTCD catalytic activity not tested\", \"Off-target effects of nanoparticle delivery not excluded\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated FTCD is a hepatic tumor suppressor in vivo and defined the signalling cascade through which its loss promotes lipid accumulation and cancer.\",\n      \"evidence\": \"Hepatocyte-specific Ftcd knockout mice, DEN-induced HCC, multi-omics, and Akt inhibitor rescue\",\n      \"pmids\": [\"37675273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How metabolic FTCD loss mechanistically engages PTEN/Akt/mTOR not fully resolved\", \"Contribution of the Golgi tethering function to tumor suppression untested\", \"Direct molecular target linking FTCD to PTEN regulation unknown\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Associated FTCD expression with therapy response, noting its downregulation in lenvatinib-resistant HCC and restoration by cabozantinib.\",\n      \"evidence\": \"Lenvatinib-resistant cell lines, xenograft proteomics, western blot, and immunohistochemistry\",\n      \"pmids\": [\"38815631\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Descriptive association only — no mechanism by which cabozantinib restores FTCD\", \"Causal role of FTCD in resistance not established\", \"Not independently confirmed\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How FTCD's metabolic enzymatic function, its Golgi membrane-tethering role, and its tumor-suppressor signalling are mechanistically integrated remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structure of the catalytic or tethering complex\", \"Whether catalytic activity is required for tumor suppression or tethering untested\", \"Direct molecular link between FTCD loss and PTEN/Akt/mTOR activation unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0016829\", \"supporting_discovery_ids\": [0]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 4]},\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3]}\n    ],\n    \"complexes\": [\"FTCD-p97/p47-FTCD tethering complex\"],\n    \"partners\": [\"NSFL1C\", \"VCP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":4,"faith_total":4,"faith_pct":100.0}}